Human health and medicine

Relatlimab

Relatlimab (BMS-986016) is a human IgG4 anti-LAG-3 monoclonal antibody from Bristol Myers Squibb; combined with nivolumab as Opdualag, it was the first LAG-3 inhibitor FDA-approved (2022) for unresectable or metastatic melanoma.

RELAX trial

RELAX trial (NCT00763867): NHLBI-sponsored randomized trial of sildenafil versus placebo in 216 HFpEF patients; no improvement in peak VO2, walk distance, or clinical status, published JAMA 2013.

Relaxation therapy

Relaxation therapy, also known as relaxation techniques, is a behavioral treatment using progressive muscle relaxation, breathing exercises, and guided imagery to reduce anxiety, stress, and insomnia.

Reldesemtiv

Reldesemtiv (CK-2127107), a second-generation fast skeletal muscle troponin activator by Cytokinetics for ALS and SMA; FORTITUDE-ALS phase 2 and COURAGE-ALS phase 3 both missed endpoints, development discontinued.

Oct 20, 2026

Relebactam anhydrous

Relebactam anhydrous (MK-7655, C12H20N4O6S, 348.38 g/mol) is a diazabicyclooctane beta-lactamase inhibitor inhibiting KPC and AmpC enzymes; combined with imipenem/cilastatin as Recarbrio, FDA-approved July 2019 for gram-negative infections.

RELEVENT trial

RELEVENT (NCT03921671) is an Italian single-arm phase II trial of ramucirumab plus carboplatin-paclitaxel as first-line therapy for untreated advanced thymic carcinoma, reporting 80% investigator ORR, 18.1-month median PFS, and 43.8-month median OS in 35 patients.

Religion and schizophrenia

Religion and schizophrenia: religious delusions affect 6–63.3% of patients, religious coping is used by up to 80%, and religiosity shapes help-seeking, adherence, and recovery.

Religious delusion

Religious delusion (ICD-11 MB26.08) is a delusion with religious or spiritual content rejected by the person's own religious group; DSM exempts culturally accepted faith, and clinical features, history, and prognosis distinguish it from belief.

Relmacabtagene autoleucel

Relmacabtagene autoleucel (relma-cel, Carteyva, JWCAR029) is JW Therapeutics' autologous anti-CD19 4-1BB CAR-T therapy, first NMPA-approved September 2021 for r/r LBCL, later FL and MCL, with Macao approval in 2025.

Relmapirazin

Relmapirazin (MB-102, Lumitrace) is a 372 Da fluorescent pyrazine tracer, cleared solely by glomerular filtration, used intravenously with the MediBeacon transdermal system for point-of-care GFR measurement; FDA approved 2025, validated against iohexol (r²=0.99), also studied orally for gut permeability.

Reloxaliase

Reloxaliase (ALLN-177) is an oral recombinant oxalate decarboxylase enzyme developed by Allena Pharmaceuticals to treat enteric hyperoxaluria; URIROX-1 showed reduced urinary oxalate, but the phase 3 URIROX-2 trial was terminated.

Reltecimod

Reltecimod (AB103, p2TA) is Atox Bio's synthetic CD28 receptor mimetic peptide for necrotizing soft tissue infections; its phase 3 ACCUTE trial (290 patients) missed the primary endpoint in the mITT population but improved organ dysfunction resolution; not approved.

Relugolix

Relugolix (Orgovyx, Myfembree) is an oral nonpeptide GnRH receptor antagonist approved by FDA in December 2020 for advanced prostate cancer; HERO showed 96.7% castration vs 88.8% with leuprolide and 54% lower MACE risk, and combination therapy treats fibroid bleeding.

Oct 20, 2026

REMAP-CAP trial

REMAP-CAP (Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia), NCT02735707, is a global adaptive platform trial launched in 2016 after the 2009 H1N1 pandemic, testing multiple pneumonia, COVID-19, and influenza treatments via Bayesian response-adaptive randomization.

REMAV-EIT trial

REMAV-EIT (NCT07402174, NCT06067152) is a Milan-based prospective cohort pilot trial of EIT-guided staircase lung recruitment maneuvers and decremental PEEP titration in 8-13 ventilated children aged 1 month to 5 years with pediatric ARDS, measuring global inhomogeneity index changes.

Remdesivir

Remdesivir (GS-5734, Veklury) is Gilead's intravenous nucleotide-analog prodrug inhibiting the SARS-CoV-2 RNA polymerase; first FDA-approved COVID-19 drug (2020), originally an unsuccessful Ebola candidate, with modest benefit in oxygen-requiring hospitalized and high-risk outpatients.

REMEDIALIV trial

REMEDIAL IV (NCT04714736), a randomized Italian trial testing the DyeVert contrast-reduction system against conventional injection in acute coronary syndrome; primary endpoints contrast volume and CA-AKI; preprint reports 95 vs 160 mL and −8.3% absolute risk difference.

Remibrutinib

Remibrutinib (Rhapsido) is Novartis's oral, highly selective covalent BTK inhibitor, approved 2025-2026 in the US, EU, UK, and Canada for chronic spontaneous urticaria in adults uncontrolled on H1-antihistamines, dosed 25 mg twice daily.

Remimazolam

Remimazolam (Byfavo, Anerem, Aptimyda) is an ultra-short-acting intravenous benzodiazepine sedative and anesthetic, metabolized by CES1 and reversible with flumazenil, first approved in Japan in 2020 for sedation and general anesthesia.

Remimazolam trial

Remimazolam trial: randomized clinical trials of remimazolam (CNS 7056), an ultra-short-acting benzodiazepine, versus propofol for endoscopic sedation and general anesthesia; remimazolam shows similar efficacy with less hypotension, respiratory depression, and injection pain.

Reminertant

Reminertant, also called meclinertant or SR 48692, is Sanofi's first non-peptide NTS1 neurotensin receptor antagonist, orally active and brain-penetrant; tested in schizophrenia and small cell lung cancer without approval.

Reminiscence therapy

Reminiscence therapy is a psychotherapeutic approach using guided recall of past life experiences, prompted by photographs, music, or objects, with the strongest evidence for reducing depressive symptoms in older adults.

Remission (medicine)

Remission (medicine): decrease or disappearance of disease signs and symptoms, short of cure. Formal criteria exist for RA (ACR/EULAR Boolean 2.0), type 2 diabetes (HbA1c <6.5%), depression, and AML.

Remission Induction

Remission induction (induction of remission) is the initial, often intensive treatment phase meant to bring a disease into remission, used in cancer (induction chemotherapy, 7+3 for AML), Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

Remission induction therapy

Remission induction therapy is the first, intensive phase of acute myeloid leukemia treatment, typically the 7+3 chemotherapy regimen given in hospital to achieve complete remission.

Remote consultation

A remote consultation is a complete episode of clinical care between patient and clinician without face-to-face contact, by telephone, video, or secure messaging, as defined in NHS England guidance.

Remote patient monitoring

Remote patient monitoring is a healthcare practice in which patients use connected medical devices to collect physiological data at home and transmit it to clinicians for review.

Remote surgery

Remote surgery, or telesurgery, is a technique in which a surgeon operates on a patient at another location by sending commands over a network to robotic instruments.

Removable Orthodontic Appliances

Removable orthodontic appliances are patient-removable dental devices (retainers, functional appliances, simple tooth-movers, clear aligners) used to close tooth gaps and guide jaw structure; first used by Kneisel in 1836, best for mild-to-moderate malocclusion.